Rhythm Pharma's Oral Drug For Rare Obesity Shows Promise

benzinga.com/news/health-care/25/07/46327353/rhythm-pharmas-oral-drug-for-rare-obesity-shows-promise

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) on Wednesday released topline results from its Phase 2 trial evaluating bivamelagon (formerly LB54640), an investigational oral melanocortin-4 receptor (MC4R) agonist, in patients with acquired hypothalamic obesity.
Hypothalamic obesity is a…

This story appeared on benzinga.com, 2025-07-09 17:35:24.
The Entire Business World on a Single Page. Free to Use →